Sortilin 1 Modulates Hepatic Cholesterol Lipotoxicity in Mice via Functional Interaction with Liver Carboxylesterase 1

Jibiao Li‡, Yifeng Wang‡, David J. Matye§, Hemantkumar Chavan‡, Partha Krishnamurthy‡, Feng Li§, and Tiangang Li†

From the ‡Department of Pharmacology, Toxicology and Therapeutics, Kansas University Medical Center, Kansas City, Kansas 66160 and the §Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030

Edited by George M. Carman

The liver plays a key role in cholesterol metabolism. Impaired hepatic cholesterol homeostasis causes intracellular free cholesterol accumulation and hepatocyte injury. Sortilin 1 (SORT1) is a lysosomal trafficking receptor that was identified by genome-wide association studies (GWAS) as a novel regulator of cholesterol metabolism in humans. Here we report that SORT1 deficiency protected against cholesterol accumulation-induced liver injury and inflammation in mice. Using an LC-MS/MS-based proteomics approach, we identified liver carboxylesterase 1 (CES1) as a novel SORT1-interacting protein. Mechanistic studies further showed that SORT1 may regulate CES1 lysosomal targeting and degradation and that SORT1 deficiency resulted in higher liver CES1 protein abundance. Previous studies have established an important role of hepatic CES1 in promoting intracellular cholesterol mobilization, cholesterol efflux, and bile acid synthesis. Consistently, high cholesterol atherogenic diet-challenged Sort1 knock-out mice showed less hepatic free cholesterol accumulation, increased bile acid synthesis, decreased biliary cholesterol secretion, and the absence of gallstone formation. SORT1 deficiency did not alter hepatic ceramide and fatty acid metabolism in high cholesterol atherogenic diet-fed mice. Finally, knockdown of liver CES1 in mice markedly increased the susceptibility to high cholesterol diet-induced liver injury and abolished the protective effect against cholesterol lipotoxicity in Sort1 knock-out mice. In summary, this study identified a novel SORT1-CES1 axis that regulates cholesterol-induced liver injury, which provides novel insights that improve our current understanding of the molecular links between SORT1 and cholesterol metabolism. This study further suggests that therapeutic inhibition of SORT1 may be beneficial in improving hepatic cholesterol homeostasis in metabolic and inflammatory liver diseases.

Sortilin 1 (SORT1) is a trans-membrane multi-ligand receptor that mainly localizes in the trans-Golgi network (TGN)² (1). A major function of SORT1 is to deliver various protein ligands in trafficking vesicles to the late endocytic compartments. Some of these proteins are lysosome-resident enzymes, and others are targeted for lysosome degradation (2, 3). A number of genome-wide association studies (GWAS) revealed that SORT1 gene was strongly associated with plasma low-density lipoprotein cholesterol levels in large human populations (4, 5), supporting an important role of SORT1 in cholesterol metabolism in humans. A number of studies have suggested that hepatic SORT1 may modulate hepatic lipoprotein production and plasma lipoprotein clearance (3, 6–10), but findings from these studies are somewhat controversial. The role and mechanisms of SORT1 regulation of cholesterol metabolism in various forms of metabolic and inflammatory diseases are incompletely understood, and further studies are required.

Hepatic cholesterol accumulation causes mitochondrial dysfunction, lysosome impairment, and hepatic injury, and has been implicated in the pathogenesis of liver diseases including non-alcoholic steatohepatitis (11–19). Here we report that mice deficient in SORT1 were protected against cholesterol-induced liver injury. Using an unbiased LC-MS/MS-based proteomics approach, we identified a novel SORT1-interacting protein called human liver carboxylesterase 1 (CES1, also known as cholesteryl ester hydrolase in humans) in HepG2 cells and mouse CES1 (also known as esterase-X (Es-X)) in mouse liver. CES1 is a neutral hydrolase for cholesterol ester and triglyceride and plays an important role in hepatic lipid mobilization (20–22). A number of previous studies have shown that CES1 prevents lipid accumulation in the liver (22–24) and in macrophages (21, 25). Of particular interest is that hepatocyte CES1 has been shown to promote cholesterol entering into the bile acid synthetic pathways for sterol elimination (20, 26). Here we showed that SORT1 may control CES1 abundance by mediating CES1 lysosomal targeting and degradation, and higher liver CES1 levels and increased bile acid synthesis may mediate

¹To whom correspondence should be addressed: Dept. of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160. Tel.: 913-588-9974; Fax: 913-588-7501; E-mail: tli@kumc.edu.

²The abbreviations used are: TGN, trans-Golgi network; FC, free cholesterol; CE, cholesteryl ester; HCD, high cholesterol diet; AST, aspartate transaminase; ALT, alanine transaminase; ACAT, acyl-CoA:cholesterol acyltransferase; LDLR, low density lipoprotein receptor; AA, amino acid; CQ, chloroquine; CA, cholic acid; CDCA, chenodeoxycholic acid; MCA, muricholic acid; UDCA, ursodeoxycholic acid; SHP, small heterodimer partner; FXR, farnesoid X receptor; IP, immunoprecipitation; Es-X, esterase-X; Ad, adenosine; STED, stimulated emission depletion; MOI, multiplicity of infection.

* This work was supported in part by an American Diabetes Association Junior Faculty Award (to T. L.), National Institutes of Health Grant 1R01DK102487-01 (to T. L.), National Center for Research Resources Grant 5P20RR021940-07, and NIGMS Grants 8 P20 GM103549-07 and P30GM118247 from the National Institutes of Health. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
the protection against cholesterol lipotoxicity in Sort1 knockout (Sort1 KO) mice. This study provides novel mechanistic insights linking liver SORT1 function to cholesterol metabolism and suggests that therapeutic inhibition of hepatic SORT1 may be beneficial in improving hepatic cholesterol homeostasis in liver diseases.

Results

SORT1-deficient Mice Show Attenuated Cholesterol-induced Liver Injury—We first challenged WT and Sort1 KO mice with a high cholesterol/cholesterol cationic diet (HCD), which has been shown to induce robust hepatic cholesterol accumulation, oxidative stress, mitochondrial impairment, and liver injury (13, 14). WT and Sort1 KO mice showed similar body weight after 1 week and 6 weeks of HCD feeding (not shown), but liver to body weight ratio was significantly lower in 6-week HCD-fed Sort1 KO mice (Fig. 1A). Livers of HCD-fed WT mice gradually showed swollen hepatocytes with pale vacuolated cytoplasm (Fig. 1B), consistent with histological characteristics of hepatocyte injury and hydropic degeneration (14, 27). These histological features were attenuated in Sort1 KO mice at both 1-week and 6-week time points (Fig. 1B). Furthermore, hepatic inflammatory infiltration, as evidenced by both H&E and F4/80 macrophage marker staining, was significantly less in 6-week HCD-fed Sort1 KO mice (Fig. 1, B and C). Consistently, 6-week HCD-fed Sort1 KO mice showed lower plasma AST and ALT levels than WT controls, suggesting attenuated liver injury (Fig. 1D). Liver monocyte chemoattractant protein 1 (MCP1) mRNA was gradually induced by HCD feeding in WT mice (Fig. 1E). Liver MCP1 mRNA was significantly lower in 1-week HCD-fed Sort1 KO mice, and trended lower in 6-week HCD-fed Sort1 KO mice when compared with WT controls (Fig. 1E). mRNA levels of hepatic cytokines TNFα and IL-1β were not induced after 1 week of HCD feeding, but were significantly induced after 6 weeks of HCD feeding in the WT group. After 6 weeks of HCD feeding, Sort1 KO mice showed significantly lower IL-1β mRNA, but not TNFα mRNA, when compared with WT controls (Fig. 1E). These results generally indicate attenuated HCD-induced liver injury in Sort1 KO mice.

HCD-fed Sort1 KO Mice Had Reduced Hepatic Free Cholesterol Accumulation—HCD feeding to WT mice caused rapid hepatic cholesterol ester (CE) and free cholesterol (FC) elevation at 1 week (Fig. 2A). At 6 weeks, hepatic FC levels continued to increase without further increase of hepatic CE levels. Because the hepatocytes respond to higher cholesterol influx by converting excessive cholesterol mainly to CE to be stored in the lipid droplets, it is possible that this ability was exceeded at 6 weeks of HCD feeding, and the liver started to accumulate more FC without further CE increase (Fig. 2, A and B). HCD-fed Sort1 KO mice accumulated significantly less FC in the liver when compared with WT mice (Fig. 2A), which is in line with attenuated liver injury in these mice. Elevated intracellular FC was shown to damage mitochondrial function as a key cause of hepatocyte injury (13). Consistently, freshly isolated liver mitochondria from HCD-fed Sort1 KO mice showed significantly improved respiratory function when compared with WT (Fig. 2B). In addition, we found that plasma AST levels, as a marker of liver injury, were strongly associated with hepatic FC levels among 6-week HCD-fed WT and Sort1 KO mice (r = 0.91) (Fig. 2C). To further determine the relationship between cellular cholesterol accumulation and cell injury, we next performed cholesterol loading in cultured HepG2 cells as an in vitro model. We showed that a modest elevation of cellular cholesterol induced by cholesterol loading was sufficient to cause cell injury as evidenced by an increased number of TUNEL-positive cells and modestly higher caspase-3 activity (Fig. 2, D–F). Furthermore, treating cells with an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor to block FC esterification to CE resulted in decreased cellular CE and increased cellular FC (Fig. 2D). Although this further cellular FC elevation caused by ACAT inhibition was very modest (~15%), it led to a significantly increased number of TUNEL-positive cells and further elevated caspase-3 activity (Fig. 2, E and F). These in vivo and in vitro results collectively suggest that cellular FC accumulation caused hepatocyte injury, and attenuated liver injury in HCD-fed Sort1 KO mice was at least partly due to lower hepatic FC accumulation.

Attenuated Liver Injury in Sort1 KO Mice Was Not due to Altered Ceramide Signaling—Cellular cholesterol and fatty acids can affect ceramide metabolism and signaling, which in turn mediates lipotoxic cell injury (28–30). The acid sphingomyelinase, which hydrolyzes sphingomyelins to ceramides in the lysosome, was shown to be involved in cytokine-induced hepatocyte death and diet-induced steatohepatitis (31). SORT1 has been implicated in the regulation of acid sphingomyelinase trafficking to the lysosomes (32). A recent study suggested that SORT1 deficiency decreased acid sphingomyelinase activity and thus may affect ceramide production in diet-induced obesity (33). We directly measured the levels of sphingolipid and fatty acid species in mouse livers. However, no differences in hepatic sphingomyelin species or C16:0 ceramide, which is the major ceramide species involved in liver injury (30), were observed between WT and Sort1 KO mice on HCD diet (Fig. 3A). In addition, hepatic triglyceride, free fatty acid species, and ketone body β-hydroxybutyrate, a marker for fatty acid oxidation, were not significantly different between WT and Sort1 KO mice (Fig. 3, B–D). These results ruled out the possible involvement of ceramide signaling in attenuated liver injury in HCD-fed Sort1 KO mice.

HCD-fed Sort1 KO Mice Showed Decreased Biliary Cholesterol Secretion and Were Protected against Gallstone Formation—Biliary cholesterol secretion is a major pathway for liver FC elimination, and was thus investigated next. We first noticed that HCD feeding for 6 weeks, but not 1 week (not shown), induced cholesterol gallstone formation in all WT mice (Fig. 4A). In contrast, no gallstones were presented in Sort1 KO mice. Biochemical measurements determined that HCD-fed Sort1 KO mice had ~50% less gallbladder cholesterol than WT mice (Fig. 4B). Both gallbladder phospholipid and bile acids tended to be higher in HCD-fed Sort1 KO mice, but these increases did not reach statistical significance (Fig. 4B). Correlation analysis further found that gallbladder total cholesterol levels strongly and positively correlated with hepatic total cholesterol levels among HCD-fed WT and Sort1 KO mice (Fig. 4C). We therefore challenged mice with HCD for 1 week and measured biliary lipid secretion rate. Consistently, Sort1 KO
FIGURE 1. Sort1 KO mice were protected against HCD-induced liver injury. WT and Sort1 KO mice were fed a chow diet or an HCD for 1 week or 6 weeks. Mice were fasted overnight (~16 h) before sacrifice. A, liver to body weight (BW) ratio. B, H&E staining of liver sections. WT+ C, WT plus chow diet; KO+ C, knock-out plus chow diet. C, F4/80 immunostaining of liver sections. Scale bar: 50 μm. D, plasma AST and ALT. E, liver mRNA expression. All results are expressed as mean ± S.E. n = 4 – 6. * indicates statistical significance, versus WT mice on same diet. # indicates statistical significance, versus chow-fed mice of the same genotype. NS, not significant.
FIGURE 2. HCD-fed Sort1 KO mice accumulated less cholesterol in the liver. WT and Sort1 KO mice were fed a chow diet or an HCD for 1 week or 6 weeks. Mice were fasted overnight before sacrifice. A, liver FC and CE levels. \( n = 4 – 6 \). * indicates statistical significance, versus WT mice on same diet. # indicates statistical significance, versus chow-fed mice of the same genotype. B, analysis of bioenergetics function of freshly isolated liver mitochondria with a Seahorse XF analyzer. Pooled liver mitochondria from 4 – 6 mice were used. Assays were done in triplicates and expressed as mean ± S.D. # indicates statistical significance, versus WT mice. Oligo, oligonucleotide; FCCP, carbonyl cyanide \( p \)-trifluoromethoxyphenylhydrazone; OCR, oxygen consumption rate; Anti-A, Antimycin A. C, correlation between liver FC and plasma AST. D–F, HepG2 cells were treated with cholesterol (Chol., complexed to methyl-\( \beta \)-cyclodextrin) and/or ACAT inhibitor (ACAT-I, 12.5 \( \mu \)g/ml) for 16 h as indicated. D, cholesterol assays were repeated in triplicates. E, TUNEL-positive cells were counted in 3 independent experiments (a total of \( \sim 1000 \) cells/group were counted). Scale bar: 50 \( \mu \)m. F, caspase-3 activity assays were repeated in triplicates. Results in D–F are expressed as mean ± S.D. # indicates statistical significance, versus untreated controls. * indicates statistical significance, versus cholesterol-treated cells (third column).
mice had significantly reduced biliary cholesterol output but similar bile acid and phospholipid output when compared with WT mice (Fig. 4D). Furthermore, fecal cholesterol excretion was similar between WT and Sort1 KO mice (Fig. 4E). Taken together, these data suggest that reduced hepatic FC accumulation in Sort1 KO mice was not due to higher biliary and fecal cholesterol excretion. On the contrary, lower hepatic cholesterol accumulation likely decreased biliary cholesterol output and prevented gallstone formation in Sort1 KO mice.

HCD-fed Sort1 KO Mice Showed Increased Hepatic Bile Acid Synthesis—Cholesterol conversion into bile acid is the most quantitatively significant pathway for cholesterol catabolism in the liver. Hepatic CYP7A1 (cholesterol 7α-hydroxylase) and CYP8B1 (sterol 12α-hydroxylase) mRNA levels were similar between WT and Sort1 KO mice under chow-fed conditions (Fig. 5A). HCD feeding significantly decreased CYP7A1 and CYP8B1 mRNA in WT mice. However, CYP7A1 was repressed to a much lesser extent in Sort1 KO mice over WT controls (Fig. 5F), suggesting that hepatic bile acid synthesis through the acidic pathway also markedly increased in Sort1 KO mice, although the mRNA of CYP27A1 (sterol 27-hydroxylase), which catalyzes the first and rate-limiting step in the acidic pathway, was not higher in these mice (Fig. 5A). Although the classic bile acid synthesis pathway produces both CA and CDCA, the acidic pathway mainly produces CDCA, the majority of which is converted to MCAs and also UDCA in mice. Therefore, stimulation of the acidic pathway may further contribute to decreased hepatic FC accumulation.

Identification of Functional SORT1-CES1 Interaction—Given that the molecular basis underlying the altered hepatic cholesterol and bile acid metabolism in Sort1 KO mice is still not clear, we reasoned that using an unbiased approach to iden-
tify SORT1-interacting proteins may help reveal novel SORT1-regulated pathways in the liver. To this end, ectopically expressed FLAG-tagged human SORT1 and its interacting proteins were co-immunoprecipitated in HepG2 cell lysate (Fig. 6A) or mouse liver lysate (not shown) and subjected to LC-MS/MS-based proteomics analysis. Many identified proteins are known SORT1 ligands such as apolipoprotein-B100 (ApoB100) (3, 6), cathepsins (2), or proteins involved in vesicle trafficking such as GGA2 (Golgi-localized, γ adaptin ear-containing, ARF-binding 2) and Rab proteins (Table 1), which thus validated this approach. CES1, which was shown to protect against cellular cholesterol and triglyceride accumulation and inflammation (22–24, 35), was identified as a SORT1-interacting protein in both HepG2 cells and mouse livers (Table 1). The SORT1-CES1 interaction was further confirmed with independent co-immunoprecipitates (co-IP) using HepG2 lysates (Fig. 6B). With validated antibodies (Fig. 6C), we confirmed that SORT1 interacted with mouse CES1 (also known as Es-X), but not CES3 (also known as triacylglycerol hydrolase (TGH)), which shares overlapping function and some degree of sequence homology with CES1 (Fig. 6D). To determine whether and how SORT1 regulates CES1, we knocked down SORT1 in HepG2 cells, which increased CES1 protein without altering CES1 mRNA (Fig. 6, E and F). Furthermore, liver CES1 protein, but not mRNA, was ~2-fold higher in Sort1 KO mice than WT mice (Fig. 6, G and H). Liver CES3 protein levels were similar in WT and Sort1 KO mice (Fig. 6G).

It is well established that SORT1 delivers many of its protein ligands to the late endosomes/lysosomes for degradation (2, 3). We therefore hypothesize that SORT1 may mediate lysosome...

FIGURE 4. HCD-fed Sort1 KO mice had decreased biliary cholesterol secretion and were protected against gallstone formation. A, gallbladder appearance and microscopic detection of crystal in the bile of 6-week HCD-fed WT and Sort1 KO mice. B, gallbladder (GB) cholesterol (Chol), phosphatidylcholine (PL), and bile acid (BA) levels. n = 4–6. C, correlation between liver total cholesterol and gallbladder cholesterol in 6-week HCD-fed WT and Sort1 KO mice. n = 4–6. D, WT and Sort1 KO mice were fed an HCD for 1 week. Mice were fasted overnight, and bile was collected via cannulation for 60 min as described under “Experimental Procedures.” n = 6–7. E, mice were fed HCD for 1 week, and feces were collected over the last 3-day period. All results are expressed as mean ± S.E. * indicates statistical significance, versus WT mice on same diet. # indicates statistical significance, versus chow-fed mice of the same genotype.
targeting of CES1, which explains why SORT1 deficiency increased CES1 abundance. To test this hypothesis, we next studied SORT1 and CES1 cellular localization in HepG2 cells. Although it is well established that SORT1 is targeted to late endocytic compartments, we consistently found that SORT1 showed predominantly perinuclear localization with significant co-localization with the Golgi marker TGN46 and minimal co-localization with late endosome/lysosome marker Lamp1 in untreated HepG2 cells (Fig. 7, A and B) and mouse liver AML12 cells (36). This is not unexpected because it is well known that SORT1 rapidly retrograde traffics back to the TGN in the retromer complex after “unloading” its ligands in the acidic environment of the late endocytic compartments (37). Because such rapid SORT1 retrograde trafficking made it difficult to study SORT1 endosome localization under basal culture conditions, we subjected HepG2 cells to short term (3-h) amino acid starvation (H1002 AA) plus chloroquine (CQ) treatment, which increased lysosome numbers and simultaneously raised late endosomal cargoes (38). This led to increased colocalization of SORT1 with the lysosomal marker LAMP1 (Fig. 7, C and D).

**FIGURE 5. HCD-fed Sort1 KO mice had increased bile acid synthesis and altered bile acid composition.** Tissues of 1-week HCD-fed mice were used for analysis. A, liver mRNA levels. B, ileum mRNA expression. WT+C, WT plus chow diet; KO+C, knock-out plus chow diet. C and D, hepatic taurine-conjugated and free bile acids (BA) determined by metabolomics analysis. Values in WT mice were set as 1. AUC, area under the curve; T, total. E, bile acid composition in gallbladder bile was analyzed by LC-MS/MS. F, liver 7α-HO-3-oxo-4-cholestenoate detected by metabolomics analysis. The value in WT was set as 1. All results are expressed as mean ± S.E. n = 5–6. * indicates statistical significance, versus WT mice on same diet. # indicates statistical significance, versus chow-fed mice of the same genotype.
FIGURE 6. Identification of functional interaction of SORT1 and CES1 in HepG2 cells and mouse livers. A, HepG2 cells were infected with Ad-null or Ad-SORT1-FLAG at an MOI of 1 for 16 h. Cell lysate was used for immunoprecipitation with anti-FLAG antibody conjugated to magnetic beads. Immunoprecipitates were subjected to SDS-PAGE and silver staining before being submitted for proteomics analysis. NC, negative control. B, HepG2 cells were infected with Ad-null or Ad-SORT1-FLAG at an MOI of 1 for 16 h. Cell lysate was used for immunoprecipitation with anti-FLAG antibody conjugated to magnetic beads. SORT1-FLAG was detected with anti-FLAG antibody. Non-infected HepG2 cell lysate was used to detect CES1 band as controls. This experiment was performed three times, and all experiments showed CES1 co-precipitation with SORT1. C, validation of CES1 and CES3 antibodies with liver lysate from Ces1 and Ces3 knock-out mice. TGH, triacylglycerol hydrolase. D, immunoprecipitation of SORT1 from mouse livers expressing SORT1-FLAG followed by Western blotting analysis. Mice were injected with Ad-null. This experiment was repeated three times, and CES1 was co-precipitated with SORT1 in all experiments. E and F, HepG2 cells were infected with Ad-shSORT1 at an MOI of 5 or 10 for 24 h. Ad-scramble was used to infect control cells. In E, Western blotting was performed to detect SORT1 and CES1 protein. Average band intensity of 3 independent experiments (normalized to actin) was shown as values below the blot. In F, real-time PCR was used to measure CES1 and SORT1 mRNA in three experiments. Results are expressed as mean ± S.D. * indicates statistical significance, versus Ad-siCon. G and H, liver protein and mRNA of WT and Sort1 KO mice on chow diet. Values below the blot indicate the relative band intensity (normalized to actin) in each group. Results are expressed as mean ± S.E. * indicates statistical significance, versus WT mice. n = 6.
endosome/lysosome pH and impaired their function. This treatment rapidly and almost completely abolished the perinuclear localization of SORT1 and caused dispersed distribution of SORT1-positive puncta throughout the cells (Fig. 7, A and B). A significant number of these SORT1-positive puncta co-localized with Lamp1 (yellow puncta indicated by white arrows in Fig. 7B), suggesting that these puncta likely represented SORT1 on the late endocytic compartments. Some SORT1-positive puncta did not co-localize with Lamp1 (green puncta indicated as red arrows in Fig. 7B), which may represent SORT1-containing trafficking vesicles before fusing with impaired late endocytic compartments. These results also implied that SORT1 dynamically traffics between the late endocytic compartments and Golgi at a high rate, which is invisible under basal culture conditions. Next, confocal microscopy analysis under these experimental conditions showed substantial SORT1-CES1 co-localization in the perinuclear region in untreated cells, whereas CES1 co-localized to SORT1-positive puncta in −AA/CQ-treated cells (indicated by white arrows in Fig. 7C). These results were further confirmed with high resolution stimulated emission depletion (STED) microscopy (Fig. 7D). These results suggest that SORT1 may interact with CES1 in trafficking vesicles that are targeted to late endocytic compartments.

Knockdown of Hepatic CES1 Increased HCD-induced Liver Injury and Abolished the Protective Effect in Sort1 KO Mice—We next reasoned that if higher CES1 indeed protects against HCD-induced liver injury, liver CES1 deficiency would exacerbate HCD-induced liver injury in mice. To test this, we acutely knocked down hepatic CES1 in WT and Sort1 KO mice with Ad-shCES1 injection (Fig. 8A). One week after injection, we fed mice an HCD for one additional week, and liver injury was studied. In Ad-scramble-injected control groups, Sort1 KO mice had significantly lower plasma AST and ALT than WT as expected (Fig. 8B). Ad-shCES1-injected WT and Sort1 KO mice showed markedly higher elevation of AST and ALT levels upon HCD challenge, and no differences were observed between WT and Sort1 KO mice fed an HCD for one additional week, and liver injury was studied. In Ad-scramble-injected control groups, Sort1 KO mice showed markedly higher elevation of AST and ALT levels (Fig. 8, A–D). Unexpectedly, knockdown of hepatic CES1 did not cause further increase of hepatic FC or CE accumulation, but markedly increased plasma cholesterol levels (Fig. 9, A–D). In Ad-scramble-injected mice, gallbladder cholesterol was significantly lower in Sort1 KO mice (Fig. 9E), which was consistent with data shown in Fig. 4B. CES1 knockdown also significantly decreased gallbladder cholesterol in WT mice but not Sort1 KO mice (Fig. 9E). The hepatic LDLR protein abundance was not significantly different between the four groups (Fig. 9F). Fig. 9G shows that hepatic CES1 knockdown mainly increased the cholesterol in VLDL and HDL fractions, although the LDL cholesterol also seemed to be modestly increased upon CES1 knockdown. It should be noted that unlike humans, mice have relatively low levels of plasma LDL cholesterol. Because VLDL particles are directly produced by the liver and they usually contain very low levels of cholesterol, the markedly elevated VLDL cholesterol suggests increased hepatic cholesterol secretion. These results collectively suggest that hepatic CES1 knockdown significantly increased the susceptibility to HCD-induced liver injury and inflammation, and abolished the protection in Sort1 KO mice. Furthermore, although increased CES1 can reduce hepatic cholesterol, CES1-deficient livers may respond to HCD challenge by secreting cholesterol into the blood circulation, resulting in hypercholesterolemia.

**Discussion**

Despite the recently identified association of SORT1 gene to cholesterol homeostasis in humans by genome-wide association studies, the role and mechanism of liver SORT1 in the regulation of cholesterol homeostasis are still incompletely understood. In this study, we provided evidence to show that SORT1 deficiency caused increased CES1 protein abundance and that SORT1 and CES1 co-localized in trafficking vesicles in HepG2 cells. Given the well documented role of SORT1 in mediating the lysosome targeting and degradation of its protein cargos (1–3), our results support the hypothesis that SORT1 mediates lysosome CES1 targeting and degradation, and SORT1 loss of function resulted in higher liver CES1. Upon an HCD challenge, Sort1 KO mice showed less hepatic FC accumulation and significantly attenuated liver injury and inflammation, which was consistent with the previously reported role of liver CES1 in protecting against cellular cholesterol accumulation and injury (22–24, 35). Therefore, this study revealed a novel SORT1-CES1 axis that modulates hepatic cholesterol metabolism in mice and further suggested that therapeutic inhibition of hepatic SORT1 may be beneficial in improving hepatic cholesterol homeostasis in liver diseases.

A number of previous studies have suggested that higher liver CES1 expression may cause further downstream metabolic changes that enhance hepatic cholesterol export or catabolism. Hepatocyte CES1 overexpression directly promoted...
cholesterol conversion into bile acids (20, 23, 26, 38). To understand the initial response to HCD challenge at an early time point that accounted for the protective effects after chronic HCD challenge in Sort1 KO mice, we studied biliary cholesterol secretion and bile acid synthesis in 1-week HCD-fed mice. Results from these experiments suggested that increased bile acid synthesis, but not higher biliary cholesterol secretion, may be responsible for lowered hepatic FC accumulation. This is supported by elevated levels of many bile acid species in the liver of HCD-fed Sort1 KO mice, especially unconjugated bile acids, a significant portion of which may be from de novo bile acid synthesis in the liver. Several mechanisms may be responsible for higher bile acid synthesis in HCD-fed Sort1 KO mice. In addition to the reported CES1 effect on stimulating liver bile acid synthesis by producing FC as the substrate, HCD-fed Sort1 KO mice also had higher CYP7A1 expression than WT controls. Dietary cholate contained in the HCD can repress hepatic CYP7A1 expression via FXR signaling in the liver and the intestine. However, the higher CYP7A1 in HCD-fed Sort1 KO mice was not likely due to altered FXR signaling because liver SHP and intestine FGF15 expression was similar in HCD-fed Sort1 KO mice and WT controls (Fig. 5, A and B). On the other hand, cholesterol feeding has also been shown to repress CYP7A1 in mice, likely due to liver inflammatory response (39, 40). Higher CYP7A1 in Sort1 KO mice correlated with lower liver FC accumulation and attenuated liver injury. Interestingly, our analysis of liver metabolites revealed a ~5-fold increase of 7α-HO-3-oxo-4-cholestenoate in Sort1 KO mice, suggesting strong stimulation of the acidic bile acid synthesis pathway in the absence of hepatic CYP27A1 induction. As previously suggested by studies in CES1-overexpressing mice (20, 26), this may be driven by increased substrate feeding into the bile acid synthetic pathway. Increased bile acid synthesis via the acidic pathway cannot only contribute to decreased hepatic FC accumula-

FIGURE 7. SORT1 and CES1 co-localization in HepG2 cells. HepG2 cells were cultured under basal condition or treated with CQ (25 μM) in amino acid-free Earle’s balanced salt solution medium for 3 h. A–C, confocal microscope images. Scale bar: 5 μm. D, STED microscope images. Scale bar: 5 μm.
tion, this may also provide a possible explanation of increased hydrophilic bile acid MCA and UDCA in the bile acid pool.

In this study, we acutely knocked down hepatic CES1 to determine the role of CES1 in the protection against cholesterol lipotoxicity in Sort1 KO mice. These studies supported a critical role of CES1 in the protection against HCD-induced hepatic injury in mice, because mice deficient in CES1 showed increased susceptibility to HCD-induced liver injury and inflammation. Interestingly, these experiments also revealed that CES1 knockdown did not cause intrahepatic cholesterol accumulation, but rather increased plasma cholesterol levels. These results suggest that CES1 gain-of-function and loss-of-function do not necessarily produce completely opposite changes of intracellular cholesterol metabolism. When liver CES1 expression is increased, CES1 can direct cholesterol into the bile acid synthesis pathway for elimination (20, 23, 26, 38). On the other hand, once hepatic CES1 is reduced, hepatocytes may instead secrete excessive cholesterol into the blood circulation as an adaptive response. This is consistent with liver’s ability to tightly control intracellular cholesterol homeostasis via fine-tuning multiple input and output pathways as an adaptive response. Nevertheless, this hypothesis needs to be further substantiated by additional experimental evidence from future investigations.

Here we mainly focused this study on the role of the SORT1-CES1 axis in the regulation of hepatic cholesterol metabolism because of the recently identified link between SORT1 and cholesterol levels in humans (4, 5). On the other hand, many studies also showed that CES1-dependent fatty acid mobilization prevented hepatic fat accumulation in mice (21, 22, 24, 35). A more recent study reported that Sort1 KO mice were protected against high fat diet-induced obesity and fatty liver, which was attributed to reduced ceramide production and signaling (33).
FIGURE 9. Hepatic CES1 knockdown increased plasma cholesterol levels without altering hepatic cholesterol accumulation in mice. The same samples as described in Fig. 8 were used for the analysis. A and B, hepatic cholesterol levels. C and D, plasma total cholesterol, CE, and FC levels. E, gallbladder total cholesterol (GB total Chol). F, hepatic LDLR protein. Band intensity (normalized to actin) was expressed as mean ± S.E. G, pooled plasma (n = 5–7) was used for determination of lipoprotein profile. All results (except G) are expressed as mean ± S.E. n = 5–7. * indicates statistical significance, versus WT mice injected with same adenovirus vector. # indicates statistical significance, versus Ad-scramble-injected mice of the same genotype.
Sortilin1 Regulation of Hepatic Cholesterol Lipotoxicity

In our experimental model, we did not observe altered hepatic sphingolipids in Sort1 KO mice. Whether the SORT1-CES1 axis plays a role in attenuating high fat diet-induced hepatic triglyceride accumulation is currently under investigation.

Taken together, this study identified a functional SORT1-CES1 axis in the liver, and thus improved current understanding of the mechanistic link between SORT1 function and cholesterol metabolism. Based on results from this study, therapeutic approaches that inhibit hepatic SORT1 function may be beneficial in attenuating hepatic cholesterol accumulation and cholesterol lipotoxicity.

Experimental Procedures

Reagents—Anti-SORT1 rabbit IgG (ab16640), anti-human CES1 (ab45957), anti-CES2 (ab137606), and anti-TGN46 (ab16059) antibodies were purchased from Abcam (Cambridge, MA). Anti-mouse CES1 (AF7929), anti-SORT1 goat IgG (AF3154), and anti-LDLR (MAB2255) were purchased from R&D Systems ( Minneapolis, MN). Actin antibody, chloroquine, and caspase-3 assay reagents were purchased from Sigma. F4/80 antibody was purchased from Bio-Rad. Anti-Lamp1 antibody was purchased from the Developmental Studies Hybridoma Bank (DSHB) at the University of Iowa. Alexa Fluor 488 IgG and Alexa Fluor 594 were purchased from Life Technologies. HepG2 cells were purchased from ATCC (Manassas, VA). AST and ALT assay kits, a total cholesterol assay kit, and a triglyceride assay kit were purchased from Pointe Scientific (Canton, MI). A free cholesterol assay kit was purchased from Wako Diagnostics (Richmond, VA). A bile acid assay kit was purchased from Diazyme Laboratories (Poway, CA). A phosphatidylcholine assay kit was purchased from BioVision (Milpitas, CA). A TUNEL assay kit was purchased from Roche Applied Science.

Mice—Global Sort1 KO mice were obtained from Taconic Biosciences Inc. The Sort1 gene (accession number: NM_019972) was silenced by inserting a stop codon into the second intron of the Sort1 gene through gene trapping technology. Mice on a 129/SvEv/C57BL/6 mixed background were purchased from Abcam (Cambridge, MA). Anti-mouse CES1 (AF7929), anti-SORT1 goat IgG (AF3154), and anti-LDLR (MAB2255) were purchased from R&D Systems ( Minneapolis, MN). Actin antibody, chloroquine, and caspase-3 assay reagents were purchased from Sigma. F4/80 antibody was purchased from Bio-Rad. Anti-Lamp1 antibody was purchased from the Developmental Studies Hybridoma Bank (DSHB) at the University of Iowa. Alexa Fluor 488 IgG and Alexa Fluor 594 were purchased from Life Technologies. HepG2 cells were purchased from ATCC (Manassas, VA). AST and ALT assay kits, a total cholesterol assay kit, and a triglyceride assay kit were purchased from Pointe Scientific (Canton, MI). A free cholesterol assay kit was purchased from Wako Diagnostics (Richmond, VA). A bile acid assay kit was purchased from Diazyme Laboratories (Poway, CA). A phosphatidylcholine assay kit was purchased from BioVision (Milpitas, CA). A TUNEL assay kit was purchased from Roche Applied Science.

Measurement of Biliary Secretion and Bile Acid Composition—Biliary secretion was measured following a previously published method (42). Briefly, WT and Sort1 KO mice were fed an HCD for 1 week and fasted overnight. After anesthesia, an ~2-cm incision was made to expose the liver and the gallbladder. The gallbladder was then cannulated with PE-10 tubing and secured with double ligation. Bile was collected by gravity into an Eppendorf tube. The bile collected for the first 10 min was discarded. Bile collected for an additional 60 min was used for bile acid, cholesterol, and phospholipid measurements with assay kits. Gallbladder bile acid composition was determined by mass spectrometry as described previously (43).

Metabolomics Analysis of Hepatic Lipids and Bile Acids—Metabolomics analysis of hepatic lipids and bile acids was performed by Metabolon Inc. (Durham, NC). Briefly, recovery standards were added based on tissue weight prior to sample extraction for data normalization. The resulting liver extract was analyzed on a Waters ACQUITY Ultra Performance Liquid Chromatography and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. Raw data were extracted and then peak-identified using Metabolon’s reference library and software. No standard curve was used, and results were expressed as relative peak area under the curve.

Lipid Analysis—Cholesterol and triglyceride were measured with colorimetric assay kits as described previously (9). Pooled plasma from 5–7 mice was used for FPLC analysis of the lipid-protein profile, which was conducted by the Mouse Metabolic Phenotyping Center (MMPC) at the University of Cincinnati.

Western Blotting—Cell lysates or liver homogenates were incubated in radioimmunoprecipitation assay buffer containing 1% SDS and protease inhibitors for 1 h on ice and sonicated briefly. Supernatant after centrifugation was used for SDS-PAGE and immunoblotting. The ImageJ software was used to quantify band intensity.

Real-time PCR—SYBR primers (Bio-Rad, Hercules, CA) were used in real-time PCR. Amplification of 18S was used for normalization. Relative mRNA expression was calculated using the comparative CT (CT) method and expressed as 2^(-ΔΔCT).

Immunofluorescence Imaging—HepG2 cells were fixed in 4% paraformaldehyde and permeabilized in 0.1% TWEEN 20 and 0.3 M glycine. Primary antibodies and Alexa Fluor-conjugated secondary antibodies were used for immunofluorescent staining. Images were acquired with either a Leica DM 5500 confocal microscope at the Kansas University Medical Center (KUMC) or a STED type super-resolution microscope (Leica TSC SP8 STED 3X) at the Molecular Cytology Core at the University of Missouri.
Statistical Analysis—Results were expressed as mean ± S.E. unless noted. Statistical analysis was performed by Student’s t test. A p < 0.05 was considered statistically significant.

Author Contributions—J. L., Y. W., and D. J. M. were involved in experimental design and conducted experiments and data collection. H. C. and P. K. determined the mitochondrial function. F. L. performed bile acid analysis. T. L. supervised the study and wrote the manuscript.

Acknowledgments—We gratefully thank Dr. Yanqiao Zhang (Northeast Ohio Medical University, Rootstown, OH) for providing the Ad-shCES1. We gratefully thank Dr. Richard Lehner (University of Alberta, Edmonton, Alberta, Canada) for providing the frozen liver tissue of Ces1 (Es-X) and Ces3 (Tgh) knock-out mice for antibody validation. We thank Robert Davison (Leica Microsystems) for assistance in acquiring STED microscope images.

References

1. Herney, G. (2009) The Vpsh3p-domain receptor family. Cell. Mol. Life Sci. 66, 2677–2689
2. Canuel, M., Korkidakis, A., Konnyu, K., and Morales, C. R. (2008) Sortilin mediates the lysosomal targeting of cathepsins D and H. Biochem. Biophys. Res. Commun. 373, 292–297
3. Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N. E., Ahfeldt, T., Sachs, K. V., Li, X., Li, H., Kuperwasser, N., Ruda, V. M., Pirrucello, J. P., Muchmore, B., Prokunina-Olsson, L., Hall, J. L., Schadt, E. E., et al. (2010) From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466, 714–719
4. Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Hoppus, A. S., Wahlstrand, B., Hedner, T., Corella, D., Tai, E. S., Ordovas, J. M., et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189–197
5. Myocardial Infarction Genetics Consortium, Kathiresan, S., Voight, B. F., Purcell, S., Musunuru, K., Aridissino, D., Mannucci, P. M., Anand, S., Engert, J. C., Samani, N. J., Schunkert, H., Erdmann, J., Reilly, M. P., Rader, D. J., Morgan, T., Spertus, J. A., Engert, J. C., Samani, N. J., Schunkert, H., Erdmann, J., Reilly, M. P., Rader, D. J., Morgan, T., Spertus, J. A., DiMaggio, P. C., Greenland, S., Kwiterovich, P. O., and Kannel, W. B. (2007) A lipidomic analysis of mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474–486
6. Van Roooyen, D. M., Larter, C. Z., Haigh, W. G., Yeh, M. Y., Ioannou, G., Permutt, M. A., Koeber, R., Lee, S. P., Teoh, N. C., and Farrell, G. C. (2011) Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141, 1393–1403, 1403 e1–5
7. Hendriks, T., Walenbergh, S. M., Holker, M. H., and Shiri-Sverdlov, R. (2014) Lysosomal cholesterol accumulation: driver on the road to inflammation during atherosclerosis and non-alcoholic steatohepatitis. Obes. Rev. 15, 424–433
8. Gan, I. T., Van Roooyen, D. M., Koika, M. E., McCuskey, R. S., Teoh, N. C., and Farrell, G. C. (2014) Hepatocyte free cholesterol lipotoxicity results from INK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J. Hepatol. 61, 1376–1384
9. Wang, Y., Ding, Y., Li, J., Chavan, H., Matye, D., Ni, H.-M., Chiang, J. Y. L., Krishnamurthy, P., Ding, W.-X., and Li, T. (2016) Targeting the endo-terepoholic bide acid signaling induces hepatic autophagy via a CYP7A1-AGT-mTOR axis in mice. Cell. Mol. Gastroenterol. Hepatol. 10.1016/j.cmg.2016.10.002
10. Zhao, B., Natarajan, R., and Ghosh, S. (2005) Human liver cholesteryl ester hydrolase cloning, molecular characterization, and role in cellular cholesterol homeostasis. Physiol. Genomics 23, 304–310
11. Ko, K. W., Erickson, B., and Lehner, R. (2009) Es/x-Ces1 prevents triacylglycerol accumulation in McArdle-RH7777 hepatocytes. Biochim. Biophys. Acta 1791, 1133–1143
12. Xu, J., Li, Y., Chen, W. D., Xu, Y., Yin, L., Ge, X., JadHAV, A., Adorini, L., and Zhang, Y. (2014) Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology 59, 1761–1771
13. Bie, J., Wang, Y., Yuan, Q., Kakiyama, G., Ghosh, S. S., and Ghosh, S. (2014) Liver-specific transgenic expression of cholesteryl ester hydrolase reduces atherosclerosis in Ldlr<sup>−/−</sup> mice. J. Lipid Res. 55, 729–738
14. Quiroga, A. D., Li, L., Trötzmüller, M., Nelson, R., Proctor, S. D., Kofeler, H., and Lehner, R. (2012) Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia. Hepatology 56, 2188–2198
15. Zhao, B., Song, J., Chow, W. N., St Clair, R. W., Rudel, L. L., and Ghosh, S. (2007) Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr<sup>−/−</sup> mice. J. Clin. Invest. 117, 2983–2992
16. Zhao, B., Song, J., and Ghosh, S. (2008) Hepatic overexpression of cholesteryl ester hydrolase enhances cholesterol elimination and in vivo reverse cholesterol transport. J. Lipid Res. 49, 2212–2217
17. Beltroy, E. P., Richardson, J. A., Horton, J. D., Turley, S. D., and Dietschy, J. M. (2005) Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease. Hepatology 42, 866–893
18. Chavez, J. A., and Summers, S. A. (2012) A ceramide-centric view of insulin resistance. Cell Metab. 15, 585–594
19. Wang, S., Robinet, P., Smith, J. D., and Gulshan, K. (2015) ORMDL orosomucoid-like proteins are degraded by free-cholesterol-loading-induced autophagy. Proc. Natl. Acad. Sci. U.S.A. 112, 3728–3733
20. Raicher, S., Wang, S. T., Chan, P. W., Li, Y., Ching, J., Chaurasia, B., Dogra, S., Ohman, M. K., Takeda, K., Sugii, S., Pewzner-Jung, Y., Futterman, A. H., and Summers, S. A. (2014) Ccr5 haploinsufficiency inhibits β-oxidation
and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 20, 687–695
31. García-Ruiz, C., Colell, A., Mari, M., Morales, A., Calvo, M., Enrich, C., and Fernández-Checa, J. C. (2003) Defective TNF-α-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J. Clin. Invest. 111, 197–208
32. Ni, X., and Morales, C. R. (2006) The lysosomal trafficking of acid sphingomyelinase is mediated by sortilin and mannose 6-phosphate receptor. Traffic 7, 889–902
33. Rabinowich, L., Fishman, S., Hubel, E., Thurm, T., Park, W. J., Pewzner-Jung, Y., Saroha, A., Erez, N., Halpern, Z., Futerman, A. H., and Zvibel, I. (2015) Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. J. Hepatol. 62, 175–181
34. Li, T., and Chiang, J. Y. (2014) Bile acid signaling in metabolic disease and drug therapy. Pharmacol. Rev. 66, 948–983
35. Bahitham, W., Watts, R., Nelson, R., Lian, J., and Lehner, R. (2016) Liver-specific expression of carboxylesterase 1g/esterase-x reduces hepatic steatosis, counteracts dyslipidemia and improves insulin signaling. Biochem. Biophys. Acta 1861, 482–490
36. Li, J., Matye, D. J., and Li, T. (2015) Insulin resistance induces post-translational hepatic sortilin 1 degradation in mice. J. Biol. Chem. 290, 11526–11536
37. Canuel, M., Lefrancois, S., Zeng, J., and Morales, C. R. (2008) AP-1 and retromer play opposite roles in the trafficking of sortilin between the Golgi apparatus and the lysosomes. Biochem. Biophys. Res. Commun. 366, 724–730
38. Yuan, Q., Bie, J., Wang, J., Ghosh, S. S., and Ghosh, S. (2013) Cooperation between hepatic cholesteryl ester hydrolase and scavenger receptor BI for hydrolysis of HDL-CE. J. Lipid Res. 54, 3078–3084
39. Henkel, A. S., Anderson, K. A., Dewey, A. M., Kavesh, M. H., and Green, R. M. (2011) A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 expression in FVB/NJ mice. J. Lipid Res. 52, 289–298
40. Li, T., Jahan, A., and Chiang, J. Y. (2006) Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology 43, 1202–1210
41. Ikonen, E. (2006) Mechanisms for cellular cholesterol transport: defects and human disease. Physiol. Rev. 86, 1237–1261
42. Baghdasaryan, A., Fuchs, C. D., Österreicher, C. H., Lemberger, U. J., Haalbasci, E., Pählman, I., Graffner, H., Krones, E., Fickert, P., Wahlström, A., Stählman, M., Paumgartner, G., Marschall, H. U., and Trauner, M. (2016) Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J. Hepatol. 64, 674–681
43. Li, T., Franch, J. M., Boehme, S., Ochoa, A., Zhang, Y., Klaassen, C. D., Erickson, S. K., and Chiang, J. Y. (2012) Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J Biol. Chem. 287, 1861–1873